

Fast Facts

Updates for Prevention and Screenings in Women's Health

Aleece Fosnight

MSPAS, PA-C, CSC-S, CSE, NCMP, IF, HAES Urology, Women's Health, Sexual Medicine Skin, Bones, Hearts, and Private Parts 2024

Objectives

- Identify components necessary for an annual wellness visit for AFAB individuals
- Discuss three vital preventative and screening topics
- List two reasons it is important to recognize special populations and considerations for their overall wellbeing.

Annual Wellness Visit

) Birth Control

Learn about choosing the right birth control method for you. Some examples include the birth control pill, intrauterine device (IUD), patch, condom, or implant.

Cancer Screening

Learn more about breast cancer, colon cancer, or other types of cancer.

Vaccinations

Get vaccinations against the flu, human papillomavirus (HPV), and more.

Health Screening

Get screened for high blood pressure, diabetes, bone density for osteoporosis, and more.



Depression Screening

Depression is a common but serious illness. Depression can be mild, moderate, or severe. To diagnose depression, your obstetrician–gynecologist or other health care provider will discuss your symptoms, how often they occur, and how severe they are.

Sexually Transmitted Infections Screening

Sexually transmitted infections (STIs), such as chlamydia, gonorrhea, and genital herpes, are infections that are spread by sexual contact.



Concerns About Sex

Discuss what happens during intercourse, pain during sex, hormonal changes that change interest or response to sex, or different forms of sex.



Issues With Your Menstrual Period

Discuss premenstrual syndrome (PMS), painful periods, your first period, heavy bleeding, or irregular periods.

Preconception Counseling

If you are planning to become pregnant, it is a good idea to have preconception counseling. Your obstetrician-gynecologist or health care provider will ask about your diet and lifestyle, your medical and family history, medications you take, and any past pregnancies.

Otl

Other Reasons

Get help with menopause symptoms, urinary incontinence, getting pregnant, or relationship problems.

> Obstetricians and Gynecologists women's Health care physicians




Copyright 2015 The American College of Obstetricians and Gynecologists

Annual Wellness Visit Specifics

- Ages 13-18
 - School, safety, relationships, contraception, suicide
- Ages 19-39
 - Reproduction, perimenopause, increased risk factors, IPV
- Ages 40-64
 - Perimenopause, menopause, mammography, colonoscopy, osteoporosis
- Ages >65
 - Menopause and risk factors

Should happen at least once a year.

Well-woman visit. ACOG Committee Opinion No. 755. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e181–86.



Cervical Cancer Screening

- New Guidelines April 2020
- Based on risk strategy risk tables to guide practice
- Routine screening applies only to asymptomatic individuals who do not require surveillance for prior abnormal screening results
- New Guidelines
 - Recommendations (colposcopy and treatment vs surveillance) are based on risk for CIN 3+
 - Risk determined by prior history as well as screen results
 - Risk tables also address 'unknown history' scenario
 - Deferral of colposcopy: Low risk for CIN 3+ (risk defined by tables)
 - Repeat HPV testing or cotesting at 1 year
 - At the 1-year follow-up test, referral to colposcopy if still abnormal
 - Expansion of expedited treatment category (biopsy not needed prior to therapy), for example, in nonpregnant patients ≥25 years, expedited treatment is
 - Preferred: CIN 3+ risk is ≥60%
 - Preferred: HPV 16–positive HSIL cytology and never or rarely screened patients with HPV-positive HSIL regardless of HPV genotype
 - Acceptable: CIN 3+ risk is between 25% and 60%
 - Shared decision making is important in the context of "impact on pregnancy outcomes"

- Excisional treatment
 - Preferred over ablation for HSIL (CIN 2 or CIN 3) in the US
 - Recommended for AIS
- CIN 1
 - Observation is preferred vs treatment
 - Treatment acceptable with persistent CIN 1 results >2 years
- Lower Anogenital Squamous Terminology (LAST)/World Health Organization (WHO) recommendations for reporting histologic HSIL
 - Include HSIL (CIN 2) and HSIL (CIN 3) (i.e., include CIN 2 and 3 qualifiers)
- Reflex cytology
 - Should be performed on all positive HPV tests, regardless of genotype
 - If HPV 16 and 18 testing is positive but additional laboratory testing of the same sample is not feasible, proceed directly to colposcopy
- Surveillance recommendations following histologic HSIL, CIN 2, CIN 3, or AIS
 - Continue surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years (recommended)
 - >25 years is acceptable "for as long as the patient's life expectancy and ability to be screened are not significantly compromised by serious health issues"
- HPV assays
 - The ASCCP consensus document states the following in reference to HPV tests

ACOG Updated Cervical Cancer Screening Guidelines April 2021, Reaffirmed April 2024

Perkins R et al. 2019 ASCCP Risk-Based Management Consensus Guidelines Committee 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and


Cancer Precursors, Journal of Lower Genital Tract Disease: April 2020 - Volume 24 - Issue 2 - p 102-131.

Egemen D et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines, Journal of Lower Genital Tract Disease: April 2020 - Volume 24 - Issue 2 - p 132-143.

Cervical Cancer Screening


American Cancer Society	American College of Obstetricians and Gynecologists	U.S. Preventative Services Task Force
 Ages 25-65 Primary hrHPV testing only every 5 	Ages 21-29Cytology alone every 3 years	Ages 21-29Cytology alone every 3 years
years	Ages 30-65	Ages 30-65
 OR HPV and cytology every 5 years 25- 64 years Cytology alone every 3 years 	 Preferred = CoTest (hrHPV and cytology) every 5 years Acceptable = Cytology alone every 3 years Can be considered = hrHPV 	 Cytology alone every 3 years hrHPV testing only every 5 years CoTest (hrHPV and cytology) every 5 years
 Ages >65 Stop if normal testing history and no history of CIN2+ 	 screening alone no more frequently than every 5 years Ages >65 Stop if normal testing history and no history of CIN2+ 	 Ages >65 Stop if normal testing history and no history of CIN2+

ASCCP management Guidelines



ASCCP Guidelines, https://www.asccp.org/screening-guidelines. Accessed February 2, 2023.

ASCCP management Guidelines




ASCCP Guidelines, https://www.asccp.org/screening-guidelines. Accessed February 2, 2023.

HPV Vaccine

- Every year in the US \rightarrow 36,500 people
- HPV vaccination could prevent more than 90% of cancers caused by HPV
- When to vaccinate?
 - Routine Age 11 to 12 years (as early as 9)
 - Catch-up Age 13 to 26 years
 - Shared decision making Adults 27 to 45 years
- HPV Vaccine dosing
 - Two doses \rightarrow 9 to 14 year olds
 - Three does \rightarrow on or after 15th birthday
- Gardasil 9 valent vaccine
 - Types 3, 6, 11, 16, 18, 31, 45, 52, 58
- We have identified over 150 strains of HPV!
 - Condyloma acuminatum = HPV-6 and HPV-11 (90%)
 - Cervical cancer = HPV-16 and HPV-18 (70%)
 - Vulvar cancer = HPV-16, HPV-18, and HPV-31 (50%)
 - Oropharyngeal = HPV-16 (60%)
 - Anal = HPV-16 and HPV-18 (90%)
- 9/10 HPV infections will clear <2 years

HPV vaccination is the best protection against certain cancers caused by HPV.



Breast Cancer Screening

American Cancer Society 2023	National Comprehensive Cancer Network 2019	U.S. Preventative Services Task Force 2024	American College of Obstetricians and Gynecologists 2024	
Mammography				
Informed decision-making with a health care provider ages 40-44.Every year starting at age 45-54.Every 2 years (or every year if a woman chooses to do so) starting at age 55, for as long as a woman is in good health.Every year starting at age 40, for as long as a woman is in good health.Informed decision-making with a health care provider ages 40-44.Every year starting at age 40, for as long as a woman is in good health.Every 2 years (or every year if a woman chooses to do so) starting at age 55, for as long as a woman is in good health.(3D mammography – breast tomosynthesis – may be considered)		Informed decision-making with a health care provider ages <40. Every 2 years ages 40-74. Insufficient evidence in ages >75.	Offer every year starting at age 40 with average risk – every one to two years. Initiate annually no later than age 50 years. May discontinue at age 75.	
Clinical Breast Exam				
Not recommended.	Every 1-3 years ages 25-39. Every year starting at age 40.	Not enough evidence to recommend for or against.	Every 1-3 years ages 25-39. Every year starting at age 40.	
Self Breast Exam				
Not recommended	Recommends breast awareness.	Not enough evidence to recommend for or against.	Recommends breast awareness.	

Berg WA. USPSTF Breast Cancer Screening Guidelines Do Not Go Far Enough. *JAMA Oncol.* Published online April 30, 2024. doi:10.1001/iamaoncol.2024.0905

Breast Cancer Screening – ABUS





Reverse Curve Transducer Having dense breasts increases a woman's likelihood to develop cancer four to six times.



BI-RADS Classification. www.acr.org. Accessed December 3, 2018.

Tice J, Migloioretti D, Li C, et al. Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol 2015; 33:3137-43.

Evaluation of a Breast Mass

- Discovered by partner or self breast exam, CBE, or screening mammography
- History
 - How long has mass been there?
 - Nipple discharge or skin changes?
 - Trauma or injury to the area?
 - Medications?
 - Relationship to menstrual cycle?
 - Family history of breast disease
- Physical exam if not found by provider on CBE, a thorough exam and inspection should be performed
 - Size, shape, consistency, mobility, location

- Diagnostic imaging
 - Under age 30 breast US
 - Over 40 diagnostic mammography with breast US as indicated
 - MRI reserved for high-risk patients
- Breast Imaging Reporting and Data System (BI-RADS) to determine need for biopsy
 - Solid masses need biopsy
 - FNA with/without US guidance
 - Core needle biopsy
 - Surgical biopsy

	BI-RADS Classification
0:	Unsatisfactory assessment – additional imaging needed
1:	Negative findings – routine follow-up recommended
2:	Benign findings – no malignancy suspected
3:	Probably benign lesion – short term follow-up indicated
4:	Suspicious abnormality
5:	Highly suggestive of malignancy
6:	Known malignancy

Benign Breast Disease

Nonproliferative Breast Lesions (Breast Cancer Risk = 1.27)

Breast cyst (simple)	Round, ovoid fluid-filled masses; firm, mobile, well-demarcated; premenopausal women (age 35-50); influenced by hormonal changes; acute enlargement can cause pain
Complex cyst	Thick walls and/or septa >0.5mm on US; anechoic or echogenic; Dx with FNA/core biopsy/surgery
Mild hyperplasia of usual type	Increase in number of epithelial cells within a duct; Dx with FNA/core biopsy/surgery
Proliferative Breast Lesions w	ithout Atypia (Breast Cancer Risk = 1.88)
Fibroadenoma	Mixed fibrous and glandular tissue; aberration of normal breast development; smooth, firm, rubbery, mobile mass; common age 15-35; Dx with core biopsy/surgery
Juvenile fibroadenoma	Unilateral, painless, rapidly growing solitary mass >5cm; ages 10-18; Tx with surgical excision
Intraductal papilloma	Wart-like growth in lactiferous ducts; small lump near nipple with clear/bloody discharge; ages 35-50; Dx with core biopsy; Tx observation vs surgical excision
Usual ductal hyperplasia	Increase in number of cells in duct without atypia, incidental finding on biopsy
Radial scars	AKA complex sclerosing lesion; fibroelastic core with radiating ducts and lobules; incidental finding
Proliferative Breast Lesions w	ith Atypia (Breast Cancer Risk = 4.24)
Atypical hyperplasia	Proliferation of dysplastic cells in ducts or lobules; 10% of biopsies; pre-malignant; Dx core biopsy; Tx with surgical excision; increased screening follow-up; avoid hormones; chemoprevention in select women

Guray M, Sahin A. Benign breast diseases: classification, diagnosis, and management. Oncologist 2006; 11:435-49.

Intimate partner violence (IPV)

- U.S. Preventive Service Task Force (USPSTF) Recommendation:
 - Screen women of childbearing age for intimate partner violence (IPV), such as domestic violence (DV), and provide or refer women who screen positive to intervention services. This recommendation applies to women who do not have signs or symptoms of abuse.
- According to the CDC, roughly 1.5 million women are raped and/or physically assaulted each year in the United States.
- IPV affects as many as 324,000 pregnant women each year.
- USPSTF screenings are directed at patients and can be self-administered or used in a clinician interview format.
- The 6 tools that showed the most sensitivity and specificity were:
 - HITS (Hurt, Insult, Threaten, Scream)
 - OVAT (Ongoing Violence Assessment Tool)
 - STaT (Slapped, Things and Threaten)
 - HARK (Humiliation, Afraid, Rape, Kick)
 - CTQ-SF (Modified Childhood Trauma Questionnaire–Short Form)
 - WAST (Woman Abuse Screen Tool)
- Other screening tools for pregnant women include 4 Ps and the Abuse Assessment Screen. CDC has compiled a comprehensive list of screening instruments that have been tested on various patient populations.
- Studies have shown that patient self-administered, or computerized screenings are as effective as clinician interviewing in terms of disclosure, comfort, and time spent screening.



Centers for Disease Control, Intimate Partner Violence, https://www.cdc.gov/media/presskits/aahd/violence.pdf

Intimate Partner Violence

Barriers

- Time constraints
- Discomfort with the topic
- Fear of offending the patient or partner
- Need for privacy
- Perceived lack of power to change the problem
- A misconception regarding patient population's risk of exposure to IPV

www.thehotline.org 1-800-799-7233

Bone Density Screening

- By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis.
- Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 year.
- The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.
- The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.
- The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteoporotic fractures in men.
 - Endocrine Society recommends for men ages >70 years
- ACOG recommends selective screening in postmenopausal women younger than 65 years who have osteoporosis risk factors or an adult fracture

Medications that may cause bone loss:

Steroid medications Thyroid hormones Anti-seizure medicines Aromatase Inhibitors Certain cancer medications Gonadotropic releasing hormone (GnRH) Proton Pump Inhibitors Selective Serotonin Reuptake Inhibitors (SSRIs) Thiazolidinediones Depo-Provera[®]

Bone Density Screening

National Osteoporosis Foundation 2014	America Association of Clinical Endocrinologists (AACE) 2020	U.S. Preventative Services Task Force 2018	American College of Obstetricians and Gynecologists 2018
Women over the age of 65	Clinical Practice Guidelines for the Diagnosis and Treatment of	All women >65 years of age	All women >65 years of age
Men over the age of 70	Postmenopausal Osteoporosis 2020	Women at increased risk for fractures, beginning at age 60	Women younger than 65 with the following risk factors:
If you break a bone after age 50	All women >65 years of age	Not enough evidence to support	History of fragility fracture Body weight less than 127 lbs
Menopausal age with risk factors	Women <65 with risk factors:	men being screened unless risk factors are present.	Medical causes of bone loss Parental history of hip fracture
Postmenopausal under age 65 with risk factors	Risk factors for falling Early menopause Smoking/Alcohol		Current smoker Alcoholism Rheumatoid arthritis
Men aged 50-69 with risk factors	Height loss kyphosis Long-term systemic glucocorticoid therapy		

The FRAX[®] Tool at www.shef.ac.uk/FRAX

USPSTF Recommendation Statement: Screening for Osteoporosis to Prevent Fractures. JAMA. 2018;319(24):2521-2531.

Colon Cancer Screening

2018 Colorectal Cancer Screening Guideline for men and women at average risk



American Cancer

ociety

Ages 45 - 75

Get screened. Several types of tests can be used. Talk to your doctor about which option is best for you.

\bigcirc	
OC	20
J.	M
	S

Ages 76 - 85

Talk to your doctor about whether you should continue screening. When deciding, take into account your own preferences, overall health, and past screening history.



Age 85 +

People should no longer get colorectal cancer screening.

TESTING OPTIONS

- Stool-based tests look for signs of cancer in a person's stool.
- Visual exams such as colonoscopy or CT colonography, look at the inside of the colon and rectum for polyps or cancer.
- No matter which test you choose, the most important thing is to get tested.

Visit cancer.org/colonguidelines to learn more.

All positive results on non-colonoscopy screening tests should be followed up with a timely colonoscopy to complete the screening process. Talk to your doctor about screening, and contact your insurance provider about insurance coverage for screening.

> ©2018, American Cancer Society, Inc. All rights reserved. The American Cancer Society is a qualified 501(c)(3) tax-exempt organization and donations are tax-deductible to the full extent of the law. 0803.90

Colon Cancer Screening

- People at average risk of colorectal cancer should start regular screening at age 45.
- People who are in good health and with a life expectancy of more than 10 years should continue regular colorectal cancer screening through the age of 75.
- People ages 76 through 85 should make a decision with their medical provider about whether to be screened, based on their own personal preferences, life expectancy, overall health, and prior screening history.
- People over 85 should no longer get colorectal cancer screening.
- What are the tests?
 - Stool-based tests:
 - Highly sensitive fecal immunochemical test (FIT) every year
 - Highly sensitive guaiac-based fecal occult blood test (gFOBT) every year
 - Multi-targeted stool DNA test (MT-sDNA) every 3 years
 - Visual exams:
 - Colonoscopy every 10 years
 - CT colonography (virtual colonoscopy) every 5 years
 - Flexible sigmoidoscopy (FSIG) every 5 years

2021 Updates to Colon Cancer Screening, American Cancer Society, https://www.cancer.org/latest-news/american-cancer-society-updates-colorectal-cancerscreening-guideline.html, accessed May 3, 2024

Depression

- The USPSTF recommends screening in all adults regardless of risk factors.
- Among older adults, risk factors for depression include disability and poor health status related to medical illness, complicated grief, chronic sleep disturbance, loneliness, and a history of depression.
- Risk factors for depression during pregnancy and postpartum
 - poor self-esteem
 - child-care stress
 - prenatal anxiety
 - life stress
 - decreased social support
 - single/unpartnered relationship status
 - history of depression
 - difficult infant temperament
 - previous postpartum depression
 - lower socioeconomic status
 - unintended pregnancy.

Screening for Depression in Adults US Preventive Services Task Force Recommendation Statement. JAMA January 26, 2016 Volume 315, Number 4.

Patient Health Questionnaire (PHQ-9)

Patient Name:			Date:			
			Not at all	Several days	More than half the days	Nearly ever day
 Over the <u>last 2 weeks</u>, how of by any of the following proble 		been bothered			nun nie days	uly
a. Little interest or pleasure in	doing thing	S				
b. Feeling down, depressed, o	r hopeless					
c. Trouble falling/staying asle	ep, sleeping	too much				
d. Feeling tired or having little	e energy					
e. Poor appetite or overeating						
f. Feeling bad about yourself of have let yourself or your far		re a failure or				
g. Trouble concentrating on the newspaper or watching tele		s reading the				
h. Moving or speaking so slowly that other people could have noticed. Or the opposite; being so fidgety or restless that you have been moving around a lot more than usual.						
 Thoughts that you would be better off dead or of hurting yourself in some way. 						
 If you checked off any proble far, how difficult have these pr your work, take care of things other people? 	roblems mad	e it for you to do	Not difficult at all	Somewhat difficult	Very difficult	Extremely difficult
Several days (#) More than half the days (#)		is 0-27. Use the ta				d the subtotal
Interpreting PHQ-9 Sc	ores		Action	ns Based on PH	19 Score	
Minimal depression Mild depression	0-4 5-9	Score <4	Action		nt may not need d	lepression
Moderately severe depression	10-14 15-19	> 5 - 14		s duration of syn	nent about treatm nptoms and funct	
Severe depression 20-27 > 15		Warrants tre		ssion, using antion nbination of treat		

* PHQ-9 is described in more detail at the McArthur Institute on Depression & Primary Care website www.depression-primarycare.org/clinicians/toolkits/materials/forms/phq9/

Anxiety

- Women are twice as likely as men to be diagnosed with anxiety disorder in their lifetime
 - 23.4% women vs 14.3% men
- Generalized anxiety disorder, panic attacks, and PTSD
- Signs and Symptoms:
 - Feeling nervous, irritable, or on edge
 - Sense of impending danger, panic, or doom
 - Increased heart rate, rapid breathing, sweating, trembling
 - Feeling weak or tired
 - Difficulty concentrating or avoidance
 - Trouble sleeping
 - Gastrointestinal problems




GAD-7 Anxiety

Over the last two weeks, how often have you been bothered by the following problems?	Not at all	Several days	More than half the days	Nearly every day
1. Feeling nervous, anxious, or on edge	0	1	2	3
2. Not being able to stop or control worrying	0	1	2	3
Worrying too much about different things	0	1	2	3
4. Trouble relaxing	0	1	2	3
Being so restless that it is hard to sit still	0	1	2	3
Becoming easily annoyed or irritable	0	1	2	3
 Feeling afraid, as if something awful might happen 	0	1	2	3

Sleep

- National Sleep Foundation recommends 7-9 hours of sleep per night for an adult
- Not current guidelines by ACOG, NAMS, USPSTF
- Should we screen for sleep issues and concerns?
- Short sleep and disturbed sleep is a causal factor for 20 percent of serious car accidents
- Poor sleep is a better predictor of developing DMT2 than lack of physical activity
- Inadequate sleep impairs brain functioning
- Cognitive and motor functioning
- 12% greater risk of mortality with fewer than 5-6 hours every night
- What is adequate?
 - 42% of your day should be reserved for rest = 10 hours



Chlamydia

STIs

Women	 Sexually active women under 25 years of age¹ Sexually active women 25 years of age and older if at increased risk*¹ Retest approximately 3 months after treatment² Rectal chlamydial testing can be considered in females based on reported sexual behaviors and exposure, through shared clinical decision between the patient and the provider^{2,3,4}
Gonorrhea	
Women	 Sovually active women under 25 years of age1

Women	 Sexually active women under 25 years of age¹
	 Sexually active women 25 years of age and older if at increased risk*¹
	Retest 3 months after treatment ²
	 Pharyngeal and rectal gonorrhea screening can be considered in females based on reported sexual behaviors and exposure, through shared clinical decision between the patient and the provider^{2,3,4}

Trichomonas

Women	Consider screening for women receiving care in high-prevalence settings (e.g., STI clinics and
	correctional facilities) and for asymptomatic women at high risk for infection (e.g., women with
	multiple sex partners, transactional sex, drug misuse, or a history of STI or incarceration) ²

Sexually Transmitted Infections Treatment Guidelines, 2021, CDC, June 6, 2022, https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm

Syphilis

STIs

Women	 Screen asymptomatic women at increased risk (history of incarceration or transactional sex work, geography, race/ethnicity) for syphilis infection^{2,7}
Herpes⁺	
Women	• Type-specific HSV serologic testing can be considered for women presenting for an STI evaluation (especially for women with multiple sex partners) ²
Hepatitis B Screer	ning
Women	 Women at increased risk (having had more than one sex partner in the previous 6 months, evaluation or treatment for an STI, past or current injection-drug use, and an HBsAg- positive sex partner)¹⁷


Hepatitis C Screening

Women	 All adults over age 18 years should be screened for hepatitis C except in settings where the hepatitis C infection (HCV) positivity is < 0.1%¹⁹

Sexually Transmitted Infections Treatment Guidelines, 2021, CDC, June 6, 2022, https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm

HIV Screening

- An estimated 1.1 million people in the United States have HIV and approximately 1 in 7 (nearly 15%) are unaware of their status
- About 40% of new HIV infections are transmitted by people undiagnosed and unaware they have HIV
- CDC recommends that EVERYONE between the ages of 13 and 64 get tested for HIV at least once as part of routine health care
- For those at higher risk, CDC recommends getting tested at least once a year
- Missed opportunities
 - More than 75% of patients at high risk for HIV who saw a PCP in the last year weren't offered an HIV test during their visit.
- Treatment
 - PrEP Pre-Exposure Prophylaxis
 - PEP Post-Exposure Prophylaxis
 - Active HIV/AIDS



Sexually Transmitted Infections Treatment Guidelines, 2021, CDC, June 6, 2022, https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm

Other Considerations

- Gender Non-Conforming
- Trans-Identified
- Queer folx



Bass B, Nagy H. Cultural Competence in the Care of LGBTQ Patients. [Updated 2022 Oct 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 January. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563176/



Thank you!

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, NCMP, IF, HAES Urology, Women's Health, Sexual Medicine Skin, Bones, Hearts, and Private Parts 2024 aleece@fosnightcenter.com @sexmedpa www.fosnightcenter.com